News

Akaal Pharma Pty Ltd has completed recruitment for a Phase-2 clinical trial involving patients with atopic dermatitis and associated pruritus

by

Greater Shepparton, Victoria, Australia, 4th June 2024. Akaal Pharma Pty Limited (Akaal) today announced that it has completed recruitment of 140 patients for its Phase 2 clinical study to evaluate safety, tolerability and efficacy of topical 1% AKP-119 in atopic dermatitis participants with pruritus. The Phase 2 clinical study is a multicentre, randomized, double blind, … Read more

Akaal Pharma Pty Ltd has received approval for a Phase-2 clinical trial involving patients with atopic dermatitis.

by

Greater Shepparton, Victoria, Australia, 3rd May 2023. Akaal Pharma Pty Limited (Akaal) today announced that it has received regulatory approval from Drugs Controller General of India (DCGI) for a Phase-2 clinical study involving 150 participants to further evaluate the safety, tolerability, and efficacy of a topical formulation of AK-119 in atopic dermatitis participants with pruritus. … Read more

Akaal Pharma Pty Ltd processed the national phase filing of its drug candidate “AK-119” and S1P1 agonist technology

by

Greater Shepparton, Victoria, Australia, 9th September 2022. Akaal Pharma Pty Limited (Akaal Pharma) today announced that it has processed filing to national phase, including the major markets, of its international patent application (PCT). Earlier, Akaal had received a favourable international preliminary report on patentability from the international patent office regarding the novelty and inventiveness of … Read more

Akaal Pharma Pty Ltd receive favourable international patent report on its drug candidate and S1P1 agonist technology

by

Greater Shepparton, Victoria, Australia, 12th May 2022. Akaal Pharma Pty Limited (Akaal Pharma) today announced that it has received a favourable preliminary patentability report from the international patent office on the novelty and inventivenessof methods of treatment with its differentiated Spingosine-1-Phosphate receptor subtype-1 (S1P1) agonist technology and lead drug candidate “AK-119”. The oral treatment with … Read more

Akaal Pharma Pty Ltd oral, First-in-Class, AK-119 is efficacious and relieve the neuropathic pain

by

Melbourne, Australia, 15th June 2021. Akaal Pharma Pty Limited (Akaal Pharma) today announced that it’s novel and differentiated Spingosine-1-Phosphate receptor subtype-1 (S1P1) agonist and lead drug candidate “AK-119” has shown efficacy in animal models of neuropathic pain. We tested AK-119 in neuropathic and nociceptive animal model of pain with significant pain-relieving effect in both disease … Read more